Yetirajam Rajesh

Dr. Yetirajam Rajesh


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
YRYetirajam Rajesh
Yetirajam Rajesh
IPIpsita Pal
Ipsita Pal
PBPayel Banik
Payel Banik
SCSandipan Chakraborty
Sandipan Chakraborty
SBSachin A Borkar
Sachin A Borkar
MMMahitosh Mandal
Mahitosh Mandal

10 May 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
APAditya Parekh
Aditya Parekh
SDSubhayan Das
Subhayan Das
SPSheetal Parida
Sheetal Parida
CDChandan Kanta Das
Chandan Kanta Das
DDDebabrata Dutta
Debabrata Dutta
MMMahitosh Mandal
Mahitosh Mandal

Verified
Journal Article
Open access
PDF file
YRYetirajam Rajesh
Yetirajam Rajesh
DSDevanand Sarkar
Devanand Sarkar
Obesity is rapidly dispersing all around the world and is closely associated with a high risk of metabolic diseases such as insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), leading to carcinogenesis, especially hepatocellular carcinoma (HCC). It results from an imbalance between food intake and energy expenditure, leading to an excessive accumulation of adipose tissue (AT). Adipocytes play a substantial role in the tumor microenvironment through the secretion of several adipokines, affecting cancer progression, metastasis, and chemoresistance via diverse signaling pathways. AT is considered an endocrine organ owing to its ability to secrete adipokines, such as leptin, adiponectin, resistin, and a plethora of inflammatory cytokines, which modulate insulin sensitivity and trigger chronic low-grade inflammation in different organs. Even though the precise mechanisms are still unfolding, it is now established that the dysregulated secretion of adipokines by AT contributes to the development of obesity-related metabolic disorders. This review focuses on several obesity-associated adipokines and their impact on obesity-related metabolic diseases, subsequent metabolic complications, and progression to HCC, as well as their role as potential therapeutic targets. The field is rapidly developing, and further research is still required to fully understand the underlying mechanisms for the metabolic actions of adipokines and their role in obesity-associated HCC.

1 January 2017 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
SPSheetal Parida
Sheetal Parida
CMChiranjit Maiti
Chiranjit Maiti
YRYetirajam Rajesh
Yetirajam Rajesh
KDKaushik K Dey
Kaushik K Dey
IPIpsita Pal
Ipsita Pal
MMMahitosh Mandal
Mahitosh Mandal

14 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YRYetirajam Rajesh
Yetirajam Rajesh
ABAngana Biswas
Angana Biswas
UKUtkarsh Kumar
Utkarsh Kumar
IBIndranil Banerjee
Indranil Banerjee
SDSubhayan Das
Subhayan Das
Paul FisherPaul Fisher
Paul Fisher
Significance: No current therapies prevent recurrence in patients with glioblastoma multiforme (GBM). Extracellular matrix (ECM) remodeling and epithelial mesenchymal transition (EMT) are important processes regulating GBM progression and acquisition of radiation and temozolomide (radio/TMZ) resistance. Fli-1 choreographs ECM remodeling and EMT in GBM via transcriptional regulation of HSPB1. Lumefantrine, an antimalarial drug, inhibits the transcriptional activities of Fli-1 and its downstream targets HSPB1, ECM remodeling, and EMT. Lumefantrine is selectively cytotoxic and promotes apoptosis in GBM and reverses radio/TMZ resistance in GBM. This drug can easily be repurposed for management of GBM. Identification of drugs like lumefantrine from FDA-approved therapeutic agents and uncommon sources provides opportunities to broaden the breadth and versatility of current therapeutic regimens for GBM.